March 7, 2002
Amersham Biosciences Corp.
Andrew Carr, Ph.D.
Venturing into Bioinformatics
What is the history of your organization’s involvement in life sciences?
Carr: Amersham Biosciences (formerly Amersham Pharmacia Biotech) has more than 60 years of experience in providing products and solutions to the life sciences market.
What is your vision for the development of the life sciences market?
Carr: Our company vision is to enable molecular medicine. That matches well to my own motivation which, along with many employees in our company, is to make available leading edge technologies and products that will ultimately be used to understand disease and thereby to improve the welfare of mankind. Our mission is to be a world leader in providing the integrated systems and solutions for disease research, drug development and drug manufacture that are needed to bring that vision closer to a reality.
What organizational assets have you developed to serve this community?
Carr: I see four key organizational assets. First, we have always believed that our future is built upon our strong R&D investment, typically well over ten percent of sales over the last several years. Second, we have also developed a very effective worldwide sales, service and support network that gives our customers, I believe, the best global support in our industry.
Third, we have focused on distinct areas of expertise: genomics, proteomics, bioassays and protein separation—giving us in-depth expertise in each area, but the ability to pull together broad, multi-disciplinary solutions. And we are in the process of developing a similar group to focus on bioinformatics to further the integration of systems and make possible data tracking across platforms. Finally, we have people who really relate to customers and their problems.
What products and services does your company provide to the life sciences market?
Carr: Amersham Biosciences’ integrated systems, products and services enable the various steps in disease research, drug discovery, development and manufacture. We have all of the major components of the process under one roof, so to speak. Our systems consist of integrated chemistry (reagents or media), hardware and software.
In disease research and drug discovery, we develop high throughput systems for gene and protein analysis and drug screening. Typically, these systems, such as the MegaBACE™ DNA Analysis System, our Ettan™-branded range of proteomics instruments and the LEADseeker™ Homogenous Imaging System, are leading edge, sophisticated technology. Other products in these areas are well-known brands in smaller instruments and a wide range of branded reagents for gene and protein analysis and bioassays.
Our protein separations business builds on the company’s 50 years of expertise in protein studies to provide systems for the purification of proteins at a laboratory scale, often during drug development, and for the production of biopharmaceuticals at an industrial scale.
Return to main index page.